Navigation Links
WuXi PharmaTech Announces Third-Quarter 2010 Results
Date:11/9/2010

include our limited operating history; failure to generate sufficient future cash flows or secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of continuing products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependence upon the continued service of our senior management and key scientific personnel; and our ability to retain our existing customers or expand our customer base.  You should read the financial information contained in this release in conjunction with the consolidated and pro-forma financial statements and related notes thereto included in our 2009 Annual Report on Form 20-F filed with and available on the Securities and Exchange Commission's website at http://www.sec.gov.  For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 6 of our 2009 Annual Report on Form 20-F.  Our results of operations for third-quarter 2009 are not necessarily indicative of our operating results for any future periods.  All projections in this release are based on limited information currently available to us, which is subject to change.  Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law.  Such information speaks only as of the date of this release.

For more information, please contact:WuXi PharmaTech (Cayman) Inc.Ronald Aldridge (for investors)Di
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility
2. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
3. Professor Steven V. Ley Speaks at WuXi PharmaTech
4. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
5. WuXi PharmaTech Announces Second-Quarter 2010 Results
6. WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call
7. WuXi PharmaTech Well Positioned to Continue Growing as Independent Company; Will Receive Breakup Fee of $30 million
8. WuXi PharmaTech Appoints Hao Zhou as Chief Financial Officer
9. WuXi PharmaTech Announces First-Quarter 2010 Results
10. WuXi PharmaTech Schedules First-Quarter 2010 Earnings Release
11. WuXi PharmaTech Enters into Collaboration with J&JPRD, a division of Janssen Pharmaceutica for Preclinical Services and Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ today ... the commercial development of the company,s supplemental oxygen ... Oxygen device, being developed by ieCrowd,s subsidiary Smart ... patient,s changing demand for oxygen based on level ... (k) submission for the Smart Oxygen device would ...
(Date:8/27/2015)... Lilly and Company (NYSE: LLY ) will attend ... 17, 2015. Sue Mahony , Ph.D., senior vice ... Gaynor , M.D., senior vice president of product development ... a fireside chat at 3:30 p.m., Eastern Daylight Time. ... available on the "Webcasts & Presentations" section of Lilly,s ...
Breaking Medicine Technology:DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... Be Useful in Cancer Treatment,Decisions , SALT LAKE ... (<a target="_blank" href=,"http://www.myriad.com/">www.myriad.com ) announced today that,it presented ... used to,determine the original location of a metastatic ... meeting of the American Association,for Cancer Research (AACR) ...
... WIRE)--Apr 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) ... results from the Phase III clinical trial,evaluating ... ALTACE(R),(ramipril) diuretic fixed-dose combination product. The Company ... expects to present the,findings in detail at ...
Cached Medicine Technology:Myriad Genetics Presents Tumor Origin Technology at AACR 2Myriad Genetics Presents Tumor Origin Technology at AACR 3King Pharmaceuticals Announces Plan to Report Positive Data from,Phase III Clinical Trial Evaluating the Combination of Altace with,Hydrochlorothiazide 2
(Date:8/28/2015)... ... ... Dr. Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and ... neck pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor ... to earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for ... is the first and only nonsurgical product approved by the Food and Drug Administration ... Quatela and Dr. William Koenig are among the premier cosmetic surgeons ...
(Date:8/28/2015)... ... 28, 2015 , ... Mendon, IL, home of the Adams County Fairgrounds, was ... for a good cause. In its second year, the “Music With A Mission” benefit ... Rehabilitation. The “Mission” of “Music With A Mission” is to raise money to help ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... evaluations for those seeking to go deep sea diving. The act of ... and decompression sickness; for these reasons, it is vital that all recreational and ...
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan ... general use any time soon, according to educational website Surviving Mesothelioma. Click here ... orphan drug designation for mesothelioma last week from the FDA, will now head into ...
Breaking Medicine News(10 mins):Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2
... VSCP ), a leading provider of quantitative ... exceeds $27 million,compared to $14.7 million at the same ... company calculates backlog as the amount remaining to be,recognized ... studies,included within the backlog ranges from 2 months to ...
... nationally recognized Consumer Watchdog sent a letter today to ... to make health care affordable and available by allowing ... group warned Obama that a proposal pushed by health ... health insurance policies "amounts only to a government-funded customer ...
... Costs as Key , , WASHINGTON, ... Excellence report looks at how states are balancing retiree health care ... , Retiree Health Care in the American States ... care benefits to central human resources (HR) goals; how the states ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s leading ... is scheduled to speak at the Piper Jaffray Healthcare Conference ... Quest Diagnostics presentation is scheduled to begin at 4:00 p.m. ... During the conference, the company will reaffirm its 2008 ...
... Patients treated with radiation prior to surgery for ... and better overall survival rates, according to a recent ... neoadjuvant therapy, which can reduce cancerous tumor size or ... the tumor. Neoadjuvant therapy may include chemotherapy and/or radiation. ...
... probably higher with aprotinin, a drug commonly used to control ... analogues, according to a study http://www.cmaj.ca//cgi/rapidpdf/cmaj.081109 to be ... , On December 3, a Health Canada expert advisory ... is being early released in advance of the meeting. ...
Cached Medicine News:Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 2Health News:Consumer Watchdog to Obama: Open Medicare to All Americans 3Health News:States View Limits on Retiree Health Benefits 2Health News:Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference 2
... automated, wireless, computerized remote temperature monitoring, ... refrigerator, freezer, incubator and water bath ... and manual temperature log reports., The ... and comes complete with installation, training ...
... water for use, it provides ... physically clean hands when routine ... an option or is not ... return to patient care faster, ...
BioSoft alcohol gel hand antiseptic with soothing moisturizers is a fast-acting, broad-spectrum antimicrobial solution. BioSoft alcohol gel hand antiseptic applies easily, requires no rinsing and dri...
Exidine® 2% CHG Brushless Surgical Scrub offers exceptional persistence and broad-spectrum antimicrobial activity....
Medicine Products: